Hematology
| aHUS
Hematology
aHUS
Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study
book_2
Source:
Blood. 2023;142(16):1371-86
calendar_today
Published on Medfyle:
December 2023
import_contacts
4
min
In this medfyle
In a recent study, researchers investigated the use of eculizumab in individuals with aHUS, a condition that can lead to kidney damage. The study found that patients treated with eculizumab had a significantly improved 5-year survival rate without progressing to end-stage kidney disease. These findings suggest that eculizumab may be an effective treatment option for individuals with aHUS, potentially preventing the progression to severe kidney damage.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
